Orphalan
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
226 Boulevard Voltaire, Paris, Ile-de-Fr...Phone Number
+33 142498264Website
www.orphalan.comRevenue
$25.3 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Orphalan
Orphalan SA is dedicated to developing innovative treatments for patients with rare diseases, particularly focusing on Wilson disease. The company aims to improve patient care and quality of life by providing access to effective therapies. With a presence in over 30 countries, Orphalan collaborates with the medical community to ensure that patients receive the necessary support and treatment. Their mission emphasizes patient-centered care, striving to make a meaningful difference in the lives of those affected by rare diseases.Explore more
Orphalan Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Orphalan your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Orphalan recently announced quarterly report
Click to see if Orphalan had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Orphalan launches new products
Congratulate Masked Content for being promoted to Masked Content at Orphalan
Funding: Get notified immidiatlly once Orphalan has new funding data
Orphalan, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Orphalan is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Orphalan has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Orphalan
Find more new buyers
Company Profile Activity
Activity Insights
Orphalan is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Orphalan is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Orphalan.
Orphalan Tech Stack
A closer look at the technologies used by Orphalan
Most Recent Scoops
Project
, according to a high-level source in sales, is planning to leverage AI-driven customer support and chatbots over the next three to six months.
Sales, Language Technology, Artificial Intelligence, Language
Project
, according to a high-level source in sales, is in the midst of initiatives related to improving sales and marketing alignment.
Sales
Project
, according to a high-level source in sales, is planning to leverage AI-driven competitive and market intelligence over the next three to six months.
Sales, Artificial Intelligence
Project
, according to a high-level source in sales, is currently in the request for proposal (RFP) stage for upcoming initiatives related to GTM technologies and tools.
Request for Proposal (RFP), Sales
Project
Automation, Sales, Artificial Intelligence
Orphalan News & Media
Orphalan becomes the first European company to enter in China's Wilson Disease market
Strategic partnership with Kyuan Xinhai (Beijing) Medical Products Trade Co., Ltd ("SPH Kyuan Trade") to transform access to Wilson's disease treatment for Chinese patients PARIS, March 7, 2025 /PRNewswire/ -- Orphalan, a global pioneer in orphan drug development and commercialization,...Behind The Mystery Unveils Treatment in Wilson Disease with Cuviror® by Orphalan
Wilson Disease, a rare, genetic disorder, hampers the body's ability to eliminate copper, leading to serious health issues. Cuvrior® (trientine tetrahydrochloride) is the only FDA-approved treatment in nearly 30 years. FORT LAUDERDALE, Fla., Aug. 19, 2024 /PRNewswire/ -- This special...Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease
Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Orphalan
Sign Up For FreeTo access detailed company insights
Orphalan SA is dedicated to developing innovative treatments for patients with rare diseases, particularly focusing on Wilson disease. The company aims to improve patient care and quality of life by providing access to effective therapies. With a presence in over 30 countries, Orphalan collaborates with the medical community to ensure that patients... Read More
